FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:413-414 January 22, 2004 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Moses, J. W. PubMed Citation

To the Editor: Although the randomized trial by Moses et al. (Oct. 2 issue)¹ shows a benefit of sirolimus-eluting stents as compared with the same bare-metal stent without drug elution (Bx Velocity), the effect on clinical restenosis is overstated. With regard to the primary end point of the trial, failure of the target vessel at nine months, the 21 percent failure rate in the control group is much higher than that with other bare-metal stents and is not representative of clinical experience with such stents. A review of six clinical trials of bare-metal stents in a total of 6186 patients . . . [Full Text of this Article]

This article has been cited by other articles:

• Valgimigli, M., Percoco, G., Malagutti, P., Campo, G., Ferrari, F., Barbieri, D., Cicchitelli, G., McFadden, E. P., Merlini, F., Ansani, L., Guardigli, G., Bettini, A., Parrinello, G., Boersma, E., Ferrari, R., for the STRATEGY Investigators, (2005). Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial. JAMA 293: 2109-2117 [Abstract] [Full Text]  
• Schwartz, R. S., Chronos, N. A., Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 44: 1373-1385 [Abstract] [Full Text]